Dianthus recasts audited financials for legacy OpCo; net loss $28.5M in 2022, going concern noted

Dianthus Therapeutics, Inc. /DE/

Net loss of $28.5M in 2022, $13.1M in 2021; accumulated deficit $45.9M at Dec 31, 2022.
Revenue from related party Zenas $6.4M in 2022, $1.5M in 2021; R&D expense $29.4M.
Cash and investments $75.5M; going concern doubt due to insufficient capital for 12 months.
Merger with Magenta closed Sep 11, 2023, accounted as reverse recapitalization; all historical shares restated at 0.2181 exchange ratio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.